Janssen Expanding Its Disease Interception Efforts
This article was originally published in The Pink Sheet Daily
Through a series of research agreements, J&J arm is seeking to create new business models teaming a single internal expert with a host of external researchers in six priority therapeutic areas.
You may also be interested in...
In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to Spectrum. Using IP from UCLA, Bloom launches with focus on neuroprotective epilepsy therapies.
CEO pledges transparency and responsible pricing of J&J drugs during the company’s earnings call, while outlining its goals for US health care and tax reform. Fourth quarter performance was unspectacular, although J&J's oncology and immunology portfolios showed sales growth.
J&J’s Robert Urban explains how his organization’s efforts lead to partnerships with academia across a broad range of areas, including pharmaceuticals, medical devices and consumer products. Also, transactions occurring between Nov. 21 and Dec. 21, including the expansion and solidification of Editas Medicine’s IP estate in CRISPR technology.